Foreword

Login or register to view PDF.
Received date
21 December 2018
Accepted date
21 December 2018
Citation
European Cardiology Review 2018;13(2):90.
DOI
https://doi.org/10.15420/ecr.2018.13.2.FO

This is a particularly exciting time for European Cardiology Review. It gives me great pleasure to announce that the journal is now indexed in PubMed. This outstanding achievement is the result of the extremely hard work of everyone involved in the journal in different capacities, in particular the publisher, Radcliffe Cardiology.

The current issue includes insightful contributions on heart failure (Lupón and Bayes-Genis), cardio-rheumatology (Mavrogeni et al.) and obesity (Conti) by international leaders in their fields.

Also, Ibrahim et al discuss the mechanisms and management of erectile dysfunction, an important condition linked to ischaemic heart disease (IHD) that affects an increasingly large proportion of individuals worldwide.

The Pharmacotherapy section of the journal is of utmost interest, featuring the pharmacogenomics of antiplatelet agents (Tan Su-Yin), whilst Guarini et al. address many novel therapeutic issues related to the use of metabolic modulators, and Facila Rubio et al. examine non-vitamin K antagonists for prevention of cardiovascular events in high-risk patients with documented IHD and those with peripheral artery disease.

Hasegawa edits a section that presents the best abstracts from the ISCP Annual Scientific Meeting 2018, which took place in Kyoto in May.

Last but not least, the Cardiology Masters section in this issue portrays the professional life of one of the most outstanding female scientists of our time, cardiac pathologist Dr Renu Virmani.

I have truly enjoyed editing this issue and hope you too will enjoy its content. With the end-of-year festivities upon us, I would like to wish you all a peaceful and prosperous New Year.